by Kristy Andrews | Jan 2, 2020 | Brain Damage, News, Traumatic Brain Injury (TBI), Veterans News
The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.
by Kristy Andrews | Dec 31, 2019 | Brain Damage, Brain Damage News, Key Brain Damage Research, Traumatic Brain Injury (TBI), Traumatic Brain Injury (TBI) News
The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.
by Extivita | Nov 12, 2019 | Concussion News, Post-Concussion Syndrome News, Post-Traumatic Stress Disorder (PTSD) News, Traumatic Brain Injury (TBI) News, Veterans News
CINCINNATI (WKRC) – Suicide among our members of the military and our veterans is now at its highest level ever, reaching an average of 24 deaths a day. Several scientific and medical studies link many of these suicides to physical brain damage suffered by...
by Extivita | Oct 26, 2019 | Concussion News, Post-Concussion Syndrome News, Traumatic Brain Injury (TBI) News
Many Oklahomans suffer from debilitating conditions resulting from head trauma. Brain injuries may result from active duty military service, sports activities, automobile accidents, and from a host of other traumatic events. State Rep. Jay Steagall (R-Yukon), chair of...
by Extivita | Oct 17, 2019 | Cancer News
Oxygen in the hyperbaric chamber provides relief after radiotherapy, new research has found. Radiotherapy is part of many treatment protocols of cancer in organs such as the prostate, cervix, ovaries, and colon and it may cause several side-effects linked to damage of...
by Kristy Andrews | Oct 7, 2019 | Anemia News, Cancer News, Myocardial Infarction News, News, Stroke News
The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture.
